Related Experiment Video

Updated: Jun 10, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism

G Pines1, P H Huang, Y Zwang

  • 1Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel.

Oncogene
|August 3, 2010
PubMed

Insights

New epidermal growth factor receptor (EGFR) mutants, EGFRvIVa and EGFRvIVb, drive glioblastoma growth by constitutively activating signaling pathways. Targeting these mutants with kinase inhibitors offers potential therapeutic strategies for aggressive brain tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Tumor cells frequently manipulate cellular signaling pathways for growth.
  • Glioblastoma multiforme is an aggressive brain tumor associated with epidermal growth factor receptor (EGFR) alterations.

Purpose of the Study:

  • To characterize novel EGFR mutants (EGFRvIVa and EGFRvIVb) found in glioblastoma.
  • To elucidate the molecular mechanisms underlying their oncogenic potential.
  • To identify potential therapeutic targets for tumors with these mutations.

Main Methods:

  • Construction and ectopic expression of EGFRvIVa and EGFRvIVb mutants.
  • In vitro oncogenic transformation assays and in vivo tumorigenesis studies.
  • Phosphoproteomic analysis to identify downstream signaling pathways.
  • Assessment of sensitivity to tyrosine kinase inhibitors and HSP90 inhibitors.

Main Results:

  • EGFRvIVa and EGFRvIVb mutants exhibit oncogenic potential in vitro and promote tumor growth in vivo.
  • Mutants lead to constitutive receptor dimerization and kinase domain activation, stabilized by HSP90.
  • Phosphoproteomic analysis revealed unique signaling pathways activated by EGFRvIVb.
  • Tumors with these mutants showed sensitivity to specific tyrosine kinase blockers and a chaperone inhibitor.

Conclusions:

  • EGFRvIVa and EGFRvIVb are oncogenic drivers in glioblastoma, acting through constitutive activation and stabilization.
  • Targeting the EGFRvIV pathway with kinase inhibitors or chaperone inhibitors presents a promising therapeutic strategy.
  • Further investigation into EGFRvIV mutations could lead to novel treatments for glioblastoma.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...